Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00482677
- Testing
- temozolomide, DNA methylation analysis, quality-of-life assessment
- Where
- 22 sites in Canada, Germany and 2 more
- Volunteers
- 562 people
- Sponsor
- Canadian Cancer Trials Group
Gastrointestinal Stromal Tumour
A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
An open label randomised trial for adults with histologically confirmed measurable metastatic GIST who have received no other treatment for metastatic disease.
- Trial name
- ALT GIST (NCT02365441)
- Testing
- Regorafenib, imatinib
- Where
- 25 sites in Australia, Finland and 8 more
- Volunteers
- 78 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs.
- Trial name
- NCT00002878
- Testing
- dexamethasone, doxorubicin hydrochloride, valspodar
- Where
- 40 sites in United States, Canada
- Sponsor
- Eastern Cooperative Oncology Group
First Progression of MGMT Promoter-methylated Glioblastoma
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
Romiplostim for low platelets caused by lomustine chemotherapy in patients with first recurrence (growing back) of a brain tumor, glioblastoma that is MGMT methylated.
- Trial name
- RIGOLETTO (NCT04933942)
- Testing
- Lomustine, Romiplostim
- Where
- 5 sites in Spain, Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Quality of Life, Cognitive Impairment
Long Term Implications of Rare Brain Tumours'
Patients diagnosed with oligodendroglioma with a specific molecular profile represent rare tumour groups (about 10% of adult gliomas) with relatively favourable prognosis (median survival between 8 and 12 years).
- Conditions
- Quality of Life, Cognitive Impairment, WHO Grade II Oligodendroglial Tumor, WHO Grade III Oligodendroglial Tumor
- Trial name
- NCT04708548
- Testing
- Health-related Quality of Life, Psychological Distress, Fatigue
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Galina Velikova
Cancer, Quality of Life
Investigating the Equivalence of the EORTC QLQ-C30 and the QLQ-F17
The EORTC QLQ-C30, a patient-reported outcome measure (PROM) that is available in 110 different languages, has been used in thousands of clinical cancer trials worldwide.
- Trial name
- NCT05479682
- Where
- Germany
- Volunteers
- 2,672 people
- Sponsor
- University Hospital Regensburg
Sarcoma
Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
- Trial name
- STRASS (NCT01344018)
- Testing
- therapeutic conventional surgery, 3-dimensional conformal radiation therapy
- Where
- 37 sites in United States, Belgium and 11 more
- Volunteers
- 266 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Ductal, Breast
Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast
Hypotheses: 1. The addition of tumour bed boost after BCS in women with non-low risk DCIS reduces the risk of local recurrence (invasive or intraductal recurrence in the ipsilateral breast). 2.
- Trial name
- DCIS (NCT00470236)
- Testing
- Standard WB fractionation, Shorter WB fractionation, Standard WB fractionation+Boost
- Where
- 120 sites in Australia, Belgium and 9 more
- Volunteers
- 1,608 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Ovarian Neoplasms
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
This is a randomized phase II study, aimed at evaluating the efficacy (through progression free survival at 6 months) and safety of 5 different treatments involving atezolizumab, bevacizumab and/or acetylsalicylic acid in…
- Trial name
- NCT02659384
- Testing
- Bevacizumab, atezolizumab, acetylsalicylic acid
- Where
- 12 sites in France, Netherlands and 3 more
- Volunteers
- 122 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Inoperable œsophageal Cancer
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
The main objective of the trial is to assess the feasibility and the safety of the addition of immunotherapy with PD-1 antibody nivolumab +/- CTLA-4 antibody ipilimumab to concomitant chemoradiation therapy (CRT) in inoperable…
- Trial name
- CRUCIAL (NCT03437200)
- Testing
- Nivolumab, Ipilimumab, Chemoradiation
- Where
- 7 sites in France, Spain
- Volunteers
- 8 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia (AML)
"InDACtion" vs "3+7" Induction in AML
Older patients with acute myeloid leukemia (AML) have a small (< 10%) chance of long-term survival. Despite the treatment of elderly AML patients with intensive chemotherapy, the survival has not been improved during the last…
- Trial name
- NCT02172872
- Testing
- standard combination chemotherapy, decitabine
- Where
- 53 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 606 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- MINDACT (NCT00433589)
- Testing
- anthracycline-based, docetaxel and capecitabine, tamoxifen
- Where
- Netherlands
- Volunteers
- 6,600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Elderly Metastatic Breast Cancer Population
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
Chemotherapy and HER2 targeted agents can improve survival significantly in metastatic breast cancer. Chemotherapy however is associated with significant side-effects and can impact on Quality of Life and functionality in older…
- Trial name
- NCT01597414
- Testing
- Pertuzumab + trastuzumab, Pertuzumab + trastuzumab + metronomic chemotherapy
- Where
- 30 sites in Belgium, France and 6 more
- Volunteers
- 80 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Neoplasms, Breast, Carcinoma of Breast
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice
- Conditions
- Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation
- Trial name
- BRAVO (NCT01905592)
- Testing
- niraparib, Physician's choice
- Where
- 104 sites in United States, Belgium and 12 more
- Volunteers
- 216 people
- Sponsor
- Tesaro, Inc.
Malignant Pleural Mesothelioma
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage MPM will be randomized between Arm A: immediate P/D followed by three cycles of chemotherapy (pemetrexed 500mg/m2 and cisplatin 75…
- Trial name
- NCT02436733
- Testing
- pleurectomy/decortication, Pemetrexed/Cisplatin
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Chronic Phase Chronic Myeloid Leukemia
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained…
- Trial name
- DASFREE (NCT01850004)
- Testing
- Dasatinib
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer
Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- CONVERT (NCT00433563)
- Testing
- Once daily radiotherapy, Twice daily radiotherapy
- Where
- United Kingdom
- Volunteers
- 547 people
- Sponsor
- The Christie NHS Foundation Trust
Colorectal Cancer, Advanced Colorectal Cancer
Screening Platform for Clinical Trials in Advanced Colorectal Cancer
The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients.
- Trial name
- SPECTAcolor (NCT01723969)
- Testing
- Tumour markers testing
- Where
- 27 sites in Belgium, Cyprus and 9 more
- Volunteers
- 668 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Platinum-Sensitive Biliary Tract Cancer
Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer
The main objective of this trial is to evaluate the activity of pamiparib plus low dose TMZ as maintenance treatment in improving progression free survival (PFS) in patients with advanced BTC who have received first line…
- Trial name
- PAMICC (NCT04796454)
- Testing
- Cisplatin, Gemcitabine, Oxaliplatin
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Liver Metastasis, Colorectal Carcinoma
A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program
This prospective database has two main objectives; to evaluate the complication rates, 30-day and 90-day mortality from different surgical strategies for unresectable, borderline resectable or initially unresectable liver…
- Trial name
- CLIMB (NCT02218801)
- Testing
- Evaluation of treatment for liver metastasis
- Where
- 16 sites in Austria, Belgium and 10 more
- Volunteers
- 219 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC